加州初创公司 Latigo Biotherapeutics 筹集了 1.35 亿美元的 A 轮资金，用于非阿片类止痛疗法的开发，包括其主导项目 LTG-001 的一期试验。 Californian start-up Latigo Biotherapeutics raises $135m Series A funding for non-opioid pain relief therapy development, including Phase 1 trial of its lead project, LTG-001.

Latigo Biotherapeutics 是一家专注于非阿片类止痛药的加州初创公司，已获得由 Westlake Village BioPartners 领投的 1.35 亿美元 A 轮融资。 Latigo Biotherapeutics, a Californian start-up focusing on non-opioid pain relief, has secured $135m in Series A funding led by Westlake Village BioPartners. Latigo 打算利用这些资金开发其非阿片类疼痛疗法组合，包括其主导项目 LTG-001，该项目正在进行针对急性和慢性疼痛的一期试验。 Latigo intends to use the funds for the development of its portfolio of non-opioid pain therapies, including its lead project, LTG-001, which is in a Phase 1 trial targeting acute and chronic pain.